Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/13678
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Poh, Ashleigh R | en |
dc.contributor.author | O'Donoghue, Robert J J | en |
dc.contributor.author | Ernst, Matthias | en |
dc.date | 2015-06-10 | en |
dc.date.accessioned | 2015-06-29T23:05:05Z | - |
dc.date.accessioned | 2015-07-15T01:16:21Z | - |
dc.date.available | 2015-06-29T23:05:05Z | - |
dc.date.available | 2015-07-15T01:16:21Z | - |
dc.date.issued | 2015-06-30 | en |
dc.identifier.citation | Oncotarget 2015; 6(18): 15751-15771 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/13678 | en |
dc.description.abstract | The hematopoietic cell kinase (HCK) is a member of the SRC family of cytoplasmic tyrosine kinases (SFKs), and is expressed in cells of the myeloid and B-lymphocyte cell lineages. Excessive HCK activation is associated with several types of leukemia and enhances cell proliferation and survival by physical association with oncogenic fusion proteins, and with functional interactions with receptor tyrosine kinases. Elevated HCK activity is also observed in many solid malignancies, including breast and colon cancer, and correlates with decreased patient survival rates. HCK enhances the secretion of growth factors and pro-inflammatory cytokines from myeloid cells, and promotes macrophage polarization towards a wound healing and tumor-promoting alternatively activated phenotype. Within tumor associated macrophages, HCK stimulates the formation of podosomes that facilitate extracellular matrix degradation, which enhance immune and epithelial cell invasion. By virtue of functional cooperation between HCK and bona fide oncogenic tyrosine kinases, excessive HCK activation can also reduce drug efficacy and contribute to chemo-resistance, while genetic ablation of HCK results in minimal physiological consequences in healthy mice. Given its known crystal structure, HCK therefore provides an attractive therapeutic target to both, directly inhibit the growth of cancer cells, and indirectly curb the source of tumor-promoting changes in the tumor microenvironment. | en |
dc.subject | SRC family kinases | en |
dc.subject | Hematopoietic cell kinase | en |
dc.subject | Cancer | en |
dc.subject | Leukemia | en |
dc.subject | SFK inhibitors | en |
dc.title | Hematopoietic cell kinase (HCK) as a therapeutic target in immune cancer cells | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Oncotarget | en |
dc.identifier.affiliation | Walter and Eliza Hall Institue of Medical Research, Department of Medical Biology, University of Melbourne, Victoria | en |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, La Trobe University School of Cancer Medicine, Victoria, Australia | en |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/26087188 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-6399-1177 | - |
dc.type.austin | Journal Article | en |
local.name.researcher | Ernst, Matthias | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ernst M (2015) Hematopoietic cell kinase.pdf | 2.63 MB | Adobe PDF | View/Open |
Page view(s)
12
checked on Mar 29, 2024
Download(s)
24
checked on Mar 29, 2024
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.